Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) Restructuring Costs (2024)

Xilio Therapeutics (XLO) has disclosed Restructuring Costs for 1 consecutive years, with -$41000.0 as the latest value for Q3 2024.

  • Quarterly Restructuring Costs changed N/A to -$41000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $937000.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $937000.0 for FY2024, N/A changed from the prior year.
  • Restructuring Costs hit -$41000.0 in Q3 2024 for Xilio Therapeutics, down from $30000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $948000.0 in Q1 2024 to a low of -$41000.0 in Q3 2024.